Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
On track to report initial Phase 1 data from HWK-007 and HWK-016 in 1H'27 Initiated Phase 1 trial for HWK-206 in the U.S., the third Whitehawk program to enter the clinic in the last 12 months; HWK-206 received Fast Track designation from the FDA Cash, cash equivalents and short-term...